JP2005502690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502690A5 JP2005502690A5 JP2003526411A JP2003526411A JP2005502690A5 JP 2005502690 A5 JP2005502690 A5 JP 2005502690A5 JP 2003526411 A JP2003526411 A JP 2003526411A JP 2003526411 A JP2003526411 A JP 2003526411A JP 2005502690 A5 JP2005502690 A5 JP 2005502690A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- chloroanilino
- pyridylmethyl
- pharmaceutical composition
- phthalazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical group 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- -1 4-pyridylmethyl Chemical group 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
Description
イバンドロン酸は、約１〜４ｍｇの範囲で変化する用量で３〜４週間ごとにヒトに投与され得る。
パミドロン酸は、約１５〜９０ｍｇの範囲で変化する用量で３〜４週間ごとにヒトに投与され得る。
Claims (7)
- (ａ)１−（４−クロロアニリノ）−４−（４−ピリジルメチル）フタラジン、(ｂ)オキサリプラチンおよび５−フルオロウラシル、ならびにフォリン酸を含み、ただしそれぞれの場合において有効成分は遊離形態または医薬上許容される塩形態で存在するものとし、さらに少なくとも１種の医薬上許容される担体を含んでいてもよい、同時、個別または連続使用される組合せ剤。
- 固形腫瘍疾患の処置に使用する、請求項１に記載の組合せ剤。
- 請求項１に記載の組合せ剤において、１−（４−クロロアニリノ）−４−（４−ピリジルメチル）フタラジンの血管形成に対して有効である量を含む、固形腫瘍疾患の処置のための医薬組成物。
- 組成物が５００ｍｇ／日〜４０００ｍｇ／日の範囲の用量の１−（４−クロロアニリノ）−４−（４−ピリジルメチル）フタラジン、またはその塩の均等内容量を含む、請求項３に記載の医薬組成物。
- 範囲が５００ｍｇ／日〜２０００ｍｇ／日である、請求項４に記載の医薬組成物。
- 組成物が５００、１０００、１５００または２０００ｍｇ／日の１−（４−クロロアニリノ）−４−（４−ピリジルメチル）フタラジン、またはその塩の均等内容量を含む、請求項５に記載の医薬組成物。
- 腫瘍疾患が結腸直腸癌である、請求項３〜６のいずれか１項に記載の医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31869401P | 2001-09-12 | 2001-09-12 | |
| US33102501P | 2001-09-12 | 2001-09-12 | |
| US32204401P | 2001-09-14 | 2001-09-14 | |
| US38816302P | 2002-06-12 | 2002-06-12 | |
| PCT/EP2002/010194 WO2003022282A1 (en) | 2001-09-12 | 2002-09-11 | Use of 4-pyridylmethylphthalazines for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502690A JP2005502690A (ja) | 2005-01-27 |
| JP2005502690A5 true JP2005502690A5 (ja) | 2009-08-06 |
Family
ID=27502161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526411A Pending JP2005502690A (ja) | 2001-09-12 | 2002-09-11 | 癌治療についての４−ピリジルメチルフタラジンの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20040258770A1 (ja) |
| EP (1) | EP1427420B1 (ja) |
| JP (1) | JP2005502690A (ja) |
| KR (1) | KR20040029172A (ja) |
| CN (1) | CN1330308C (ja) |
| AT (2) | ATE421880T1 (ja) |
| AU (2) | AU2002342678B2 (ja) |
| BR (1) | BR0212446A (ja) |
| CA (1) | CA2457848A1 (ja) |
| CO (1) | CO5560545A2 (ja) |
| CY (1) | CY1105189T1 (ja) |
| DE (2) | DE60231068D1 (ja) |
| DK (1) | DK1427420T3 (ja) |
| ES (2) | ES2266590T3 (ja) |
| HR (1) | HRP20040241A2 (ja) |
| IL (1) | IL160382A0 (ja) |
| NO (1) | NO327358B1 (ja) |
| NZ (1) | NZ531484A (ja) |
| PL (1) | PL367349A1 (ja) |
| PT (1) | PT1427420E (ja) |
| RS (1) | RS16804A (ja) |
| WO (1) | WO2003022282A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0223341D0 (en) * | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
| WO2004058234A2 (en) * | 2002-12-27 | 2004-07-15 | Schering Aktiengesellschaft | Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors |
| WO2004105747A1 (en) * | 2003-05-20 | 2004-12-09 | Aronex Pharmaceuticals, Inc | Combination chemotherapy comprising capecitabine and a liposomal platinum complex |
| US20080085902A1 (en) * | 2003-09-23 | 2008-04-10 | Guido Bold | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent |
| GB0610925D0 (en) * | 2006-06-02 | 2006-07-12 | Novartis Ag | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer |
| KR101037292B1 (ko) * | 2010-09-03 | 2011-05-27 | (주)슈추어 | 신발 장식구 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2224130T3 (es) * | 1994-08-09 | 2005-03-01 | Eisai Co., Ltd. | Compuesto de piridazina condensada. |
| KR100489174B1 (ko) * | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| US6096904A (en) * | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
-
2002
- 2002-09-11 ES ES02779338T patent/ES2266590T3/es not_active Expired - Lifetime
- 2002-09-11 KR KR10-2004-7003645A patent/KR20040029172A/ko active IP Right Grant
- 2002-09-11 EP EP02779338A patent/EP1427420B1/en not_active Expired - Lifetime
- 2002-09-11 DK DK02779338T patent/DK1427420T3/da active
- 2002-09-11 AT AT06114903T patent/ATE421880T1/de not_active IP Right Cessation
- 2002-09-11 NZ NZ531484A patent/NZ531484A/en not_active IP Right Cessation
- 2002-09-11 IL IL16038202A patent/IL160382A0/xx not_active IP Right Cessation
- 2002-09-11 WO PCT/EP2002/010194 patent/WO2003022282A1/en active Application Filing
- 2002-09-11 CN CNB028178831A patent/CN1330308C/zh not_active Expired - Fee Related
- 2002-09-11 BR BR0212446-7A patent/BR0212446A/pt not_active IP Right Cessation
- 2002-09-11 PL PL02367349A patent/PL367349A1/xx not_active Application Discontinuation
- 2002-09-11 AU AU2002342678A patent/AU2002342678B2/en not_active Ceased
- 2002-09-11 AT AT02779338T patent/ATE329597T1/de not_active IP Right Cessation
- 2002-09-11 CA CA002457848A patent/CA2457848A1/en not_active Abandoned
- 2002-09-11 ES ES06114903T patent/ES2320922T3/es not_active Expired - Lifetime
- 2002-09-11 PT PT02779338T patent/PT1427420E/pt unknown
- 2002-09-11 DE DE60231068T patent/DE60231068D1/de not_active Expired - Lifetime
- 2002-09-11 DE DE60212415T patent/DE60212415T2/de not_active Expired - Lifetime
- 2002-09-11 US US10/489,751 patent/US20040258770A1/en not_active Abandoned
- 2002-09-11 RS YUP-168/04A patent/RS16804A/sr unknown
- 2002-09-11 JP JP2003526411A patent/JP2005502690A/ja active Pending
-
2004
- 2004-02-27 CO CO04017661A patent/CO5560545A2/es active IP Right Grant
- 2004-03-05 NO NO20040973A patent/NO327358B1/no not_active IP Right Cessation
- 2004-03-11 HR HR20040241A patent/HRP20040241A2/hr not_active Application Discontinuation
-
2006
- 2006-08-09 AU AU2006203428A patent/AU2006203428B2/en not_active Ceased
- 2006-08-31 CY CY20061101239T patent/CY1105189T1/el unknown
-
2009
- 2009-04-15 US US12/423,843 patent/US20090196871A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007515469A5 (ja) | ||
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| JP2019517542A5 (ja) | ||
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JP2002528502A5 (ja) | ||
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| JP2002524415A5 (ja) | ||
| JP2006502132A5 (ja) | ||
| JP2005522527A5 (ja) | ||
| HUP0303466A2 (hu) | Eljárás és adagolási forma tumorok tegafur, uracil, folinsav, paclitaxel és carboplatin beadásával való kezelésére | |
| RU2003100507A (ru) | Фармацевтические композиции | |
| US8664268B2 (en) | Gallium compositions for the treatment of liver cancer and methods of use | |
| JP2004529207A5 (ja) | ||
| JP2005502690A5 (ja) | ||
| JP2002540148A5 (ja) | ||
| US6602870B2 (en) | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same | |
| CA2504665A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| JP2002326936A5 (ja) | ||
| JP2001508769A (ja) | アレンドロン酸塩及び胃排出を促進する薬剤を含有する医薬組成物 | |
| JP2023011549A5 (ja) | ||
| JP2002536333A5 (ja) | ||
| JP4707668B2 (ja) | オキソプラチン、その塩および誘導体を含む医薬組成物 | |
| CA2576926A1 (en) | Use of midostaurin for treating gastrointestinal stromal tumors | |
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ |